LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review
LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...
LENZ Therapeutics
CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...